Botulism physical examination

Jump to navigation Jump to search

Botulism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Botulism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Botulism physical examination On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Botulism physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Botulism physical examination

CDC on Botulism physical examination

Botulism physical examination in the news

Blogs on Botulism physical examination

Directions to Hospitals Treating Botulism

Risk calculators and risk factors for Botulism physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Keanu Ngo[2]

Overview

The physical examination of botulism classically reveals an afebrile, alert patient with symmetric, descending flaccid paralysis beginning in the cranial nerves, with preserved sensation and mental status. The most useful examination findings are bilateral cranial-nerve deficits (ptosis, ophthalmoplegia, facial weakness, diminished gag), autonomic/cholinergic signs (dilated poorly reactive pupils, dry mucous membranes, ileus), symmetric descending weakness with diminished or absent reflexes, and signs of evolving neuromuscular respiratory failure. In infants, the hallmark is generalized hypotonia ("floppy baby") with bulbar findings.[1][2][3]

General appearance and vital signs

  • Appearance: alert and oriented despite marked weakness; may appear lethargic purely because of facial/bulbar weakness and ptosis. Sensorium is preserved (toxin does not cross the blood–brain barrier).[4]
  • Temperature: characteristically afebrile (no fever in 99% of a 332-case CDC series). Fever suggests a superimposed infection or a wound abscess in wound botulism.[5][6]
  • Autonomic instability: orthostatic hypotension and labile heart rate/blood pressure may be present in both adults and infants; bradycardia can occur.[7][8]

HEENT and cranial-nerve examination

Bilateral, symmetric cranial-nerve deficits are the diagnostic core; at least one ocular weakness finding was present in 84% of the CDC series:[9][10]

  • Eyes: ptosis, ophthalmoplegia/extraocular movement limitation, sluggish or absent pupillary light reflex. Dilated, fixed or poorly reactive pupils are present in about half of patients and are a key autonomic sign. Nystagmus is not characteristic.[11]
  • Face: symmetric facial weakness, loss of facial expression.
  • Mouth/throat: dry mucous membranes, dysarthria, dysphonia, diminished gag reflex, pooling of oropharyngeal secretions, tongue weakness.[12]

Neuromuscular examination

  • Motor: symmetric weakness in a descending pattern (cranial → neck → upper limbs → trunk → lower limbs), proximal ≥ distal.[13]
  • Reflexes: deep tendon reflexes are diminished or absent; they may be normal early and decline as paralysis progresses.[14]
  • Sensory: normal (no true sensory loss); paresthesias are uncommon.[15]

Respiratory examination

Serial bedside respiratory assessment drives disposition. Watch for tachypnea, shallow breathing, weak cough, staccato/breathy speech, use of accessory muscles, and paradoxical abdominal movement (diaphragmatic weakness). Bulbar and facial weakness can mask typical distress signs (grimacing, nasal flaring). Hypoxemia and hypercarbia are late; the decision to intubate should be based on clinical trajectory and bedside measures, not blood gases alone. Serial measurement of vital capacity and negative inspiratory force at the bedside helps track respiratory decline.[16]

Abdominal and skin examination

  • Abdomen: distension with decreased/absent bowel sounds (ileus), reflecting autonomic cholinergic blockade.[17]
  • Skin (wound botulism): inspect for wounds, injection sites/track marks, subcutaneous granulomas ("skin popping"), cellulitis, or abscess; a wound may appear benign despite toxin production.[18]

Infant examination

  • General: hypotonic ("floppy"), expressionless facies, feeble/weak cry, poor head control.[19]
  • Cranial nerves: ptosis (against gravity), ocular palsies, sluggish pupils, diminished gag/suck/swallow reflexes.<ref name="Cox2002">{{cite journal |author=Cox N; Hinkle R |title
  1. ↑ American Academy of Pediatrics (2024). Botulism and Infant Botulism (Clostridium botulinum). Red Book: 2024–2027 Report of the Committee on Infectious Diseases.
  2. ↑ Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.
  3. ↑ Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  4. ↑ Liu SC; Poon JT; Candee MS (2021). "Clinical Reasoning: A Teenager With Shortness of Breath and Difficulty Walking". Neurology.
  5. ↑ Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  6. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  7. ↑ Chalk CH; Benstead TJ; Pound JD; Keezer MR (2019). "Medical treatment for botulism". Cochrane Database of Systematic Reviews. 4: CD008123. doi:10.1002/14651858.CD008123.pub4.
  8. ↑ Freeman R (2005). "Autonomic Peripheral Neuropathy". Lancet.
  9. ↑ Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  10. ↑ Gayed SMA; Motley MP; Carlson JM; Lupu KS; Mavrogiorgos N (2026). "The Eyes Have It". The New England Journal of Medicine. 394 (10): 1011–1017. doi:10.1056/NEJMcps2508044.
  11. ↑ Schreck KC; Schneider L; Geocadin RG (2015). "Clinical Reasoning: A 44-Year-Old Woman With Rapidly Progressive Weakness and Ophthalmoplegia". Neurology.
  12. ↑ American Academy of Pediatrics (2024). Botulism and Infant Botulism (Clostridium botulinum). Red Book: 2024–2027 Report of the Committee on Infectious Diseases.
  13. ↑ Chalk CH; Benstead TJ; Pound JD; Keezer MR (2019). "Medical treatment for botulism". Cochrane Database of Systematic Reviews. 4: CD008123. doi:10.1002/14651858.CD008123.pub4.
  14. ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
  15. ↑ Rao AK; Lin NH; Jackson KA; Mody RK; Griffin PM (2017). "Clinical Characteristics and Ancillary Test Results Among Patients With Botulism—United States, 2002-2015". Clinical Infectious Diseases. PMID 29293936.
  16. ↑ Berkwitt A; El Saleeby CM; Murphy SA (2024). "Case 3-2024: An 8-Week-Old Male Infant with Inconsolable Crying and Weakness". The New England Journal of Medicine.
  17. ↑ Freeman R (2005). "Autonomic Peripheral Neuropathy". Lancet.
  18. ↑ Schreck KC; Schneider L; Geocadin RG (2015). "Clinical Reasoning: A 44-Year-Old Woman With Rapidly Progressive Weakness and Ophthalmoplegia". Neurology.
  19. ↑ American Academy of Pediatrics (2024). Botulism and Infant Botulism (Clostridium botulinum). Red Book: 2024–2027 Report of the Committee on Infectious Diseases.